Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.07
DEPO's Cash to Debt is ranked lower than
95% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. DEPO: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s 10-Year Cash to Debt Range
Min: 0.07  Med: 16.43 Max: No Debt
Current: 0.07
Equity to Asset 0.26
DEPO's Equity to Asset is ranked lower than
91% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DEPO: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s 10-Year Equity to Asset Range
Min: -2.63  Med: 0.39 Max: 0.97
Current: 0.26
-2.63
0.97
Interest Coverage 9.90
DEPO's Interest Coverage is ranked lower than
80% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. DEPO: 9.90 )
Ranked among companies with meaningful Interest Coverage only.
DEPO' s 10-Year Interest Coverage Range
Min: 1.73  Med: 5265.78 Max: 9999.99
Current: 9.9
1.73
9999.99
F-Score: 3
Z-Score: 1.80
M-Score: -0.69
WACC vs ROIC
19.18%
20.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 39.56
DEPO's Operating margin (%) is ranked higher than
96% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. DEPO: 39.56 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91  Med: -171.43 Max: 72.49
Current: 39.56
-12972.91
72.49
Net-margin (%) 18.18
DEPO's Net-margin (%) is ranked higher than
84% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. DEPO: 18.18 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35  Med: -171.43 Max: 75.05
Current: 18.18
-14964.35
75.05
ROE (%) 22.40
DEPO's ROE (%) is ranked higher than
83% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. DEPO: 22.40 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s 10-Year ROE (%) Range
Min: -1190.93  Med: -53.49 Max: 532.43
Current: 22.4
-1190.93
532.43
ROA (%) 8.60
DEPO's ROA (%) is ranked higher than
71% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. DEPO: 8.60 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s 10-Year ROA (%) Range
Min: -201.37  Med: -43.28 Max: 73.87
Current: 8.6
-201.37
73.87
ROC (Joel Greenblatt) (%) 56.22
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. DEPO: 56.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2282.52  Med: -659.26 Max: 8060.52
Current: 56.22
-2282.52
8060.52
Revenue Growth (3Y)(%) 35.50
DEPO's Revenue Growth (3Y)(%) is ranked higher than
93% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DEPO: 35.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -69.7  Med: 25.55 Max: 420.5
Current: 35.5
-69.7
420.5
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. DEPO: 43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DEPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.8  Med: 6.85 Max: 84.2
Current: 43.2
-55.8
84.2
EPS Growth (3Y)(%) 16.50
DEPO's EPS Growth (3Y)(%) is ranked higher than
67% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DEPO: 16.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5  Med: -6.25 Max: 180.9
Current: 16.5
-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

DEPO Guru Trades in Q3 2014

Steven Cohen 448,900 sh (New)
Joel Greenblatt 1,637,713 sh (+74.77%)
Paul Tudor Jones 64,690 sh (+61.27%)
George Soros Sold Out
» More
Q4 2014

DEPO Guru Trades in Q4 2014

Joel Greenblatt 1,218,263 sh (-25.61%)
Paul Tudor Jones 42,365 sh (-34.51%)
Steven Cohen 151,800 sh (-66.18%)
» More
Q1 2015

DEPO Guru Trades in Q1 2015

Joel Greenblatt 1,414,563 sh (+16.11%)
Paul Tudor Jones 42,414 sh (+0.12%)
Steven Cohen Sold Out
» More
Q2 2015

DEPO Guru Trades in Q2 2015

Paul Tudor Jones 26,100 sh (-38.46%)
Joel Greenblatt 842,188 sh (-40.46%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DepoMed Inc

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 36.19
DEPO's P/E(ttm) is ranked lower than
59% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. DEPO: 36.19 )
Ranked among companies with meaningful P/E(ttm) only.
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36  Med: 8.88 Max: 121.85
Current: 36.19
2.36
121.85
Forward P/E 19.23
DEPO's Forward P/E is ranked higher than
58% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. DEPO: 19.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 38.40
DEPO's PE(NRI) is ranked lower than
58% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. DEPO: 38.40 )
Ranked among companies with meaningful PE(NRI) only.
DEPO' s 10-Year PE(NRI) Range
Min: 2.36  Med: 8.96 Max: 123.38
Current: 38.4
2.36
123.38
P/B 4.63
DEPO's P/B is ranked lower than
68% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. DEPO: 4.63 )
Ranked among companies with meaningful P/B only.
DEPO' s 10-Year P/B Range
Min: 2  Med: 4.55 Max: 48.18
Current: 4.63
2
48.18
P/S 4.72
DEPO's P/S is ranked lower than
67% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. DEPO: 4.72 )
Ranked among companies with meaningful P/S only.
DEPO' s 10-Year P/S Range
Min: 1.38  Med: 3.63 Max: 530
Current: 4.72
1.38
530
PFCF 42.35
DEPO's PFCF is ranked lower than
52% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. DEPO: 42.35 )
Ranked among companies with meaningful PFCF only.
DEPO' s 10-Year PFCF Range
Min: 2.37  Med: 9.36 Max: 307.17
Current: 42.35
2.37
307.17
POCF 41.03
DEPO's POCF is ranked lower than
68% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. DEPO: 41.03 )
Ranked among companies with meaningful POCF only.
DEPO' s 10-Year POCF Range
Min: 2.29  Med: 9.23 Max: 276.45
Current: 41.03
2.29
276.45
EV-to-EBIT 20.90
DEPO's EV-to-EBIT is ranked higher than
55% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. DEPO: 20.90 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s 10-Year EV-to-EBIT Range
Min: -208.4  Med: -3.10 Max: 130
Current: 20.9
-208.4
130
Shiller P/E 55.87
DEPO's Shiller P/E is ranked lower than
74% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. DEPO: 55.87 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s 10-Year Shiller P/E Range
Min: 21.62  Med: 54.86 Max: 123.75
Current: 55.87
21.62
123.75
Current Ratio 1.71
DEPO's Current Ratio is ranked lower than
65% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. DEPO: 1.71 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s 10-Year Current Ratio Range
Min: 0.57  Med: 3.24 Max: 56
Current: 1.71
0.57
56
Quick Ratio 1.63
DEPO's Quick Ratio is ranked lower than
51% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. DEPO: 1.63 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s 10-Year Quick Ratio Range
Min: 0.57  Med: 3.03 Max: 56
Current: 1.63
0.57
56
Days Inventory 89.98
DEPO's Days Inventory is ranked higher than
61% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. DEPO: 89.98 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s 10-Year Days Inventory Range
Min: 93.22  Med: 226.72 Max: 613.73
Current: 89.98
93.22
613.73
Days Sales Outstanding 58.50
DEPO's Days Sales Outstanding is ranked higher than
62% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. DEPO: 58.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s 10-Year Days Sales Outstanding Range
Min: 12.13  Med: 45.80 Max: 54004.13
Current: 58.5
12.13
54004.13

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 5.75
DEPO's Price/Projected FCF is ranked lower than
76% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. DEPO: 5.75 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s 10-Year Price/Projected FCF Range
Min: 1.18  Med: 3.46 Max: 335
Current: 5.75
1.18
335
Price/Median PS Value 1.37
DEPO's Price/Median PS Value is ranked lower than
60% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. DEPO: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.41  Med: 3.29 Max: 123.5
Current: 1.37
0.41
123.5
Earnings Yield (Greenblatt) (%) 4.75
DEPO's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 4.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.8  Med: 16.00 Max: 251.9
Current: 4.75
0.8
251.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 332 480 586
EPS($) 0.65 1.40 1.88
EPS without NRI($) 0.65 1.40 1.88

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany,
DepoMed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed Sets Record Date in Response to Horizon Bid Aug 31 2015
DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 31 2015
Wannabe buyer appeals to shareholders in contentious East Bay takeover Aug 28 2015
This Analyst Loves Depomed And Its Nucynta Prescription Aug 28 2015
Depomed, Inc. Earnings Q2, 2015 Aug 26 2015
'Haphazard approach' turns $2 billion East Bay takeover bid into snippy affair Aug 21 2015
DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 21 2015
Horizon Pharma's failed Depomed buyout Aug 20 2015
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc Aug 20 2015
Depomed rejects Horizon Pharma's offer for the third time Aug 19 2015
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc Aug 19 2015
Horizon Pharma Appears to Be on an Acquisition Spree Aug 17 2015
Horizon Pharma PLC -- Moody's: Horizon's new Depomed offer reduces upward credit pressure Aug 13 2015
Horizon Pharma Talks to Depomed Holders About Adding Cash Aug 13 2015
Depomed Comments on Horizon Pharma plc Letter Aug 13 2015
Depomed Comments on Horizon Pharma plc Letter Aug 13 2015
Investor Alert: Investigation of Depomed Announced by Holzer & Holzer, LLC Aug 10 2015
DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 10 2015
DEPOMED INC Financials Aug 08 2015
SHAREHOLDER ALERT: The Wagner Firm Announces Investigation of the Board of Directors of DepoMed,... Aug 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK